Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis Gait Disorders, Neurologic | Device: Ekso GT™ exoskeleton | Not Applicable |
Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some improvements in sitting, standing and walking posture when used consistently. The investigator is not aware of any study of the Ekso GT™ exoskeleton in MS.
This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5). Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients with MS.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 5 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis |
Actual Study Start Date : | July 23, 2019 |
Actual Primary Completion Date : | January 9, 2020 |
Actual Study Completion Date : | January 9, 2020 |
Arm | Intervention/treatment |
---|---|
gait training with exoskeleton device
uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
|
Device: Ekso GT™ exoskeleton
The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Device-Specific Criteria
Assessed by physical therapy:
Exclusion Criteria:
• MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to enrollment
Assessed by physical therapy:
United States, Ohio | |
Cleveland Clinic Neurological Institute Mellen Center | |
Cleveland, Ohio, United States, 44195 |
Principal Investigator: | Francois A Bethoux, MD | The Cleveland Clinic |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 6, 2019 | ||||||
First Posted Date ICMJE | June 27, 2019 | ||||||
Results First Submitted Date ICMJE | February 25, 2020 | ||||||
Results First Posted Date ICMJE | April 7, 2020 | ||||||
Last Update Posted Date | April 7, 2020 | ||||||
Actual Study Start Date ICMJE | July 23, 2019 | ||||||
Actual Primary Completion Date | January 9, 2020 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
|
||||||
Original Primary Outcome Measures ICMJE |
|
||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
Timed 25 Foot Walk [ Time Frame: 0-14 weeks ] Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis | ||||||
Official Title ICMJE | Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis | ||||||
Brief Summary | The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist. This is a small PI-initiated uncontrolled pilot study to gather safety and feasibility data on the exoskeleton in individuals with MS and walking impairment. | ||||||
Detailed Description |
Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some improvements in sitting, standing and walking posture when used consistently. The investigator is not aware of any study of the Ekso GT™ exoskeleton in MS. This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5). Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients with MS. |
||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population Masking: None (Open Label)Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Device: Ekso GT™ exoskeleton
The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
|
||||||
Study Arms ICMJE | gait training with exoskeleton device
uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Intervention: Device: Ekso GT™ exoskeleton
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
5 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Actual Study Completion Date ICMJE | January 9, 2020 | ||||||
Actual Primary Completion Date | January 9, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Device-Specific Criteria
Assessed by physical therapy:
Exclusion Criteria:
Assessed by physical therapy:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT04000373 | ||||||
Other Study ID Numbers ICMJE | 19-580 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Responsible Party | Francois Bethoux, MD, The Cleveland Clinic | ||||||
Study Sponsor ICMJE | The Cleveland Clinic | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | The Cleveland Clinic | ||||||
Verification Date | March 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |